Business Wire

Ascend Expands Antimicrobial Acteev™ Technology Into Finished Goods Line to Combat COVID-19 Spread

10.9.2020 17:53:00 EEST | Business Wire | Press release

Share

A new line of face masks combining comfort with protection is available from Acteev™ by Ascend Performance Materials, a manufacturer of technology-forward textiles and engineered materials. The brand’s first product, the Acteev Protect™ Nonwoven Mask, is a reusable general purpose mask that features powerful built-in antimicrobial technology to protect the mask from odor-causing bacteria and mold fungi in a soft, breathable, comfortable fabric that is gentle on the skin.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200910005748/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Acteev Protect Nonwoven Mask is a reusable general purpose mask that features powerful built-in antimicrobial technology to protect the mask from odor-causing bacteria and mold fungi in a soft, breathable, comfortable fabric that is gentle on the skin. (Photo: Business Wire)

The mask is the first in a series of planned Acteev product introductions that will include a knit fabric mask and a sports gaiter. The company also announced it is designing an N95 respirator and a line of surgical masks and is developing more engineering plastics solutions for high-touch surfaces such as light switches and tray tables; textiles for use in scrubs and hospital gowns; and nonwoven fibers and rolled goods for use in applications such as filtration systems.

The expansion into masks is a natural extension for Ascend, which is the largest producer of nylon 6,6 resin in the world, said Lu Zhang, Ph.D., who joined Ascend earlier this year as vice president and leader of the Acteev business. “The nylon Ascend makes is durable enough to be used under the hood of a car, but when it’s spun into fibers, it can be woven or knitted into fabrics that are soft and silky,” she said. “Combined with our antimicrobial Acteev technology, our fabric makes an Acteev Protect Nonwoven Mask more breathable, more comfortable and more wearable than anything else we’ve encountered in the market.”

The Acteev Protect Nonwoven Mask is an ideal choice for anyone seeking better protection, comfort and breathability than a typical blue mask and better availability than an N95 respirator, which are reserved for health care workers, Zhang said.

“Masks only inhibit the spread if they’re worn – that’s why comfort and breathability are so important,” Zhang said. “As we send our kids back to school, return to the workplace, resume shopping and otherwise get back to normal life, we need an option that is long-lasting and wearable for hours.

“They’re great for teachers, restaurant staff, transportation workers, industrial personnel and anyone whose lifestyle takes them out of their homes and into the world,” Zhang said.

Darayus Pardivala, the president of the Americas division of Sulzer Rotating Equipment Services, purchased the masks for employees at all 32 of the company’s locations in North and South America. “They’re much easier to breathe through compared to what we had in the past, there’s an added level of protection and our employees are much more comfortable,” Pardivala said. “The pushback we had in the past about wearing masks is completely gone.”

Recent testing on the knit fabric completed at the University of Cambridge has demonstrated that Acteev technology deactivates the virus that causes COVID-19, SARS-CoV-2, with 99.9% efficacy on contact1. Ascend is working with the U.S. Environmental Protection Agency, the U.S. Food and Drug Administration and other governmental agencies to obtain the appropriate regulatory clearances to make specific claims regarding the technology’s antiviral properties.

Acteev Protect Nonwoven Masks are made with Acteev™ technology with active zinc ions in a polymer matrix to destroy microbes.

“Acteev’s active layer of defense uses safe, environmentally friendly active zinc ions embedded into the matrix of the polymer – not a chemical spray that will wash away or flake off – meaning these masks can be used again and again,” said Phil McDivitt, CEO of Ascend.

The Acteev Protect Nonwoven Masks are constructed with three layers of zinc-embedded materials.

“Our scientists and engineers invented a process for creating a revolutionary new fabric that checks all the boxes,” McDivitt said. “Acteev™ fabric is soft to the touch and moisture-wicking to keep the face cool, and it’s more breathable than other materials used in masks.”

Product availability can be found at acteev.com and on social media: @acteevbyascend on Instagram, Twitter and Facebook.

About Ascend Performance Materials

Ascend Performance Materials makes high-performance materials for everyday essentials and new technologies. Our focus is on improving quality of life and inspiring a better tomorrow through innovation. Based in Houston, Texas, and with regional offices in Shanghai, Brussels and Detroit, we are a fully integrated material solutions provider with eight global manufacturing facilities in the United States, Europe and China. Our 2,600-person global workforce makes the plastics, fabrics, fibers and chemicals used to make safer vehicles, cleaner energy, better medical devices, smarter appliances and longer-lasting apparel and consumer goods. We are committed to safety, sustainability and the success of our customers and our communities.

Find out more about Ascend at www.ascendmaterials.com.

About Acteev: acteev.com

  • Tests show >99% antiviral, antibacterial, antifungal efficacy1
  • EPA-registered zinc ions embedded in the polymer
  • Hygroscopic nylon 6,6 fabric attracts moisture, which activates the zinc ions
  • Not a topical treatment or coating
  • Not dependent on silver, copper
  • Proven efficacy in many end forms:
    • Knit and woven fabrics for consumer textiles, upholstery, uniforms, face masks
    • Nanofiber, meltblown and spunbond nonwovens for filtration
    • Fibers for carpets
    • Engineered plastics for high-touch surfaces

1DISCLAIMER: Acteev™ technology has been shown in laboratory tests to destroy SARS-CoV-2, the coronavirus that causes COVID-19, and other pathogens including H1N1, coronavirus 229E and Gram-positive and Gram-negative bacteria such as staphylococcus and E. coli. All data presented on this page comes from testing performed by independent third-party laboratories. Testing conducted on various end forms. Testing by University of Cambridge found a >3 log (99.9%) reduction in SARS-CoV-2 and H1N1 viruses upon instant contact on polyamide 66 textile fabric with Acteev technology as compared to an identical basis weight polyamide 66 textile fabric without Acteev technology. Acteev Protect does not protect users or others against disease-causing bacteria. Not all claims are permitted in all jurisdictions, including in the United States. Some device designs currently under review with the U.S. Food and Drug Administration. Ascend has more than 15 patent families pending on Acteev technology.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Nicki Britton, +1 832-205-4854, nbritt@ascendmaterials.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye